Deoxypalytoxin
| Internal ID | c59b53f7-8468-4bd5-942b-7487974e3c36 |
| Taxonomy | Lipids and lipid-like molecules > Prenol lipids > Terpene glycosides |
| IUPAC Name | (E,2S,3R,5R,8R,9S)-10-[(2R,3R,4R,5S,6R)-6-[(1S,2R,3S,4S,5R,11S)-12-[(1R,3S,5S,7R)-5-[(8S)-9-[(2R,3R,4R,5R,6S)-6-[(E,2S,3S,6S,9R,10R)-10-[(2S,4R,5S,6R)-6-[(2R,3R)-4-[(2R,3S,4R,5R,6S)-6-[(3Z,5E,8R,9S,10R,12Z,17S,18R,19R,20R)-21-[(2R,3R,4R,5S,6R)-6-[(Z,3R,4R)-5-[(1S,3R,5R,7R)-7-[2-[(2R,3R,5S)-5-(aminomethyl)-3-hydroxyoxolan-2-yl]ethyl]-2,6-dioxabicyclo[3.2.1]octan-3-yl]-3,4-dihydroxypent-1-enyl]-3,4,5-trihydroxyoxan-2-yl]-8,9,10,17,18,19-hexahydroxy-20-methyl-14-methylidenehenicosa-3,5,12-trienyl]-3,4,5-trihydroxyoxan-2-yl]-2,3-dihydroxybutyl]-4,5-dihydroxyoxan-2-yl]-2,6,9,10-tetrahydroxy-3-methyldec-4-enyl]-3,4,5,6-tetrahydroxyoxan-2-yl]-8-hydroxynonyl]-1,3-dimethyl-6,8-dioxabicyclo[3.2.1]octan-7-yl]-1,2,3,4,5-pentahydroxy-11-methyldodecyl]-3,4,5-trihydroxyoxan-2-yl]-2,5,8,9-tetrahydroxy-N-[(E)-3-(3-hydroxypropylamino)-3-oxoprop-1-enyl]-3,7-dimethyldec-6-enamide |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C129H223N3O53/c1-63(31-35-81(142)108(157)103(152)69(7)49-94-112(161)118(167)111(160)92(180-94)38-37-76(137)82(143)52-73-51-74-54-93(177-73)90(176-74)40-39-89-85(146)53-75(62-130)178-89)25-22-29-78(139)105(154)77(138)27-18-12-9-13-20-30-91-110(159)117(166)113(162)97(179-91)56-84(145)83(144)55-95-107(156)87(148)58-96(181-95)106(155)80(141)36-34-70(134)33-32-66(4)88(149)61-129(175)125(173)123(172)115(164)99(183-129)50-71(135)26-17-11-10-14-21-42-128-60-65(3)59-127(8,185-128)100(184-128)46-64(2)24-16-15-19-28-79(140)109(158)116(165)120(169)122(171)124-121(170)119(168)114(163)98(182-124)57-86(147)102(151)67(5)47-72(136)48-68(6)104(153)126(174)132-44-41-101(150)131-43-23-45-133/h9,12-13,18,22,25,32-33,37-38,41,44,47,64-66,68-100,102-125,133-149,151-173,175H,1,10-11,14-17,19-21,23-24,26-31,34-36,39-40,42-43,45-46,48-62,130H2,2-8H3,(H,131,150)(H,132,174)/b13-9-,18-12+,25-22-,33-32+,38-37-,44-41+,67-47+/t64-,65-,66-,68+,69+,70+,71-,72-,73-,74+,75-,76+,77+,78+,79+,80+,81-,82+,83+,84+,85+,86-,87+,88-,89+,90+,91-,92+,93-,94+,95+,96-,97+,98+,99+,100+,102+,103+,104-,105-,106+,107-,108+,109-,110-,111+,112-,113+,114-,115-,116-,117+,118-,119+,120+,121-,122-,123+,124-,125+,127+,128-,129-/m0/s1 |
| InChI Key | GNUXTROKUYRQMR-DJTXWYTBSA-N |
| Popularity | 4 references in papers |
| Molecular Formula | C129H223N3O53 |
| Molecular Weight | 2664.10 g/mol |
| Exact Mass | 2663.4880338 g/mol |
| Topological Polar Surface Area (TPSA) | 1010.00 Ų |
| XlogP | -5.50 |
| Atomic LogP (AlogP) | -7.61 |
| H-Bond Acceptor | 54 |
| H-Bond Donor | 44 |
| Rotatable Bonds | 80 |
| DTXSID201334979 |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.7164 | 71.64% |
| Caco-2 | - | 0.8583 | 85.83% |
| Blood Brain Barrier | - | 0.8250 | 82.50% |
| Human oral bioavailability | - | 0.6429 | 64.29% |
| Subcellular localzation | Mitochondria | 0.5749 | 57.49% |
| OATP2B1 inhibitior | - | 0.8636 | 86.36% |
| OATP1B1 inhibitior | + | 0.7944 | 79.44% |
| OATP1B3 inhibitior | + | 0.9363 | 93.63% |
| MATE1 inhibitior | - | 0.9012 | 90.12% |
| OCT2 inhibitior | - | 0.9000 | 90.00% |
| BSEP inhibitior | + | 0.9494 | 94.94% |
| P-glycoprotein inhibitior | + | 0.7416 | 74.16% |
| P-glycoprotein substrate | + | 0.8668 | 86.68% |
| CYP3A4 substrate | + | 0.7670 | 76.70% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8639 | 86.39% |
| CYP3A4 inhibition | - | 0.9257 | 92.57% |
| CYP2C9 inhibition | - | 0.8665 | 86.65% |
| CYP2C19 inhibition | - | 0.8465 | 84.65% |
| CYP2D6 inhibition | - | 0.9186 | 91.86% |
| CYP1A2 inhibition | - | 0.8708 | 87.08% |
| CYP2C8 inhibition | + | 0.8826 | 88.26% |
| CYP inhibitory promiscuity | - | 0.9377 | 93.77% |
| UGT catelyzed | + | 0.6000 | 60.00% |
| Carcinogenicity (binary) | - | 0.9600 | 96.00% |
| Carcinogenicity (trinary) | Non-required | 0.4815 | 48.15% |
| Eye corrosion | - | 0.9843 | 98.43% |
| Eye irritation | - | 0.8961 | 89.61% |
| Skin irritation | - | 0.7224 | 72.24% |
| Skin corrosion | - | 0.9172 | 91.72% |
| Ames mutagenesis | - | 0.5678 | 56.78% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7517 | 75.17% |
| Micronuclear | + | 0.6900 | 69.00% |
| Hepatotoxicity | + | 0.5584 | 55.84% |
| skin sensitisation | - | 0.8313 | 83.13% |
| Respiratory toxicity | + | 0.7444 | 74.44% |
| Reproductive toxicity | + | 0.9667 | 96.67% |
| Mitochondrial toxicity | + | 0.9625 | 96.25% |
| Nephrotoxicity | - | 0.5864 | 58.64% |
| Acute Oral Toxicity (c) | III | 0.5955 | 59.55% |
| Estrogen receptor binding | + | 0.7136 | 71.36% |
| Androgen receptor binding | + | 0.7724 | 77.24% |
| Thyroid receptor binding | + | 0.7171 | 71.71% |
| Glucocorticoid receptor binding | + | 0.8066 | 80.66% |
| Aromatase binding | + | 0.6887 | 68.87% |
| PPAR gamma | + | 0.8229 | 82.29% |
| Honey bee toxicity | - | 0.5833 | 58.33% |
| Biodegradation | - | 0.8250 | 82.50% |
| Crustacea aquatic toxicity | - | 0.5600 | 56.00% |
| Fish aquatic toxicity | + | 0.8797 | 87.97% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.87% | 91.11% |
| CHEMBL325 | Q13547 | Histone deacetylase 1 | 99.24% | 95.92% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.10% | 98.95% |
| CHEMBL204 | P00734 | Thrombin | 97.60% | 96.01% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 97.47% | 96.09% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 97.09% | 99.17% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 96.86% | 97.09% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 96.67% | 94.73% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 96.41% | 100.00% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 96.33% | 90.17% |
| CHEMBL4793 | Q86TI2 | Dipeptidyl peptidase IX | 96.31% | 96.95% |
| CHEMBL4657 | Q6V1X1 | Dipeptidyl peptidase VIII | 96.31% | 97.21% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 96.27% | 94.75% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 95.13% | 95.93% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 94.91% | 100.00% |
| CHEMBL2563 | Q9UQL6 | Histone deacetylase 5 | 94.86% | 89.67% |
| CHEMBL1907602 | P06493 | Cyclin-dependent kinase 1/cyclin B1 | 94.82% | 91.24% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 93.41% | 89.00% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 93.09% | 97.29% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 92.41% | 93.56% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 91.97% | 93.10% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 91.90% | 96.47% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 91.75% | 98.33% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 91.65% | 98.05% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 91.53% | 91.19% |
| CHEMBL2964 | P36507 | Dual specificity mitogen-activated protein kinase kinase 2 | 91.26% | 80.00% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 91.22% | 85.14% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 91.06% | 86.33% |
| CHEMBL2001 | Q9H244 | Purinergic receptor P2Y12 | 90.60% | 96.00% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 90.34% | 96.38% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 89.77% | 97.14% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 89.76% | 92.32% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 89.42% | 95.71% |
| CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 88.80% | 96.00% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 88.74% | 95.89% |
| CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 88.62% | 98.75% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 88.57% | 96.11% |
| CHEMBL3091268 | Q92753 | Nuclear receptor ROR-beta | 88.49% | 95.50% |
| CHEMBL236 | P41143 | Delta opioid receptor | 88.28% | 99.35% |
| CHEMBL2007 | P16234 | Platelet-derived growth factor receptor alpha | 88.23% | 91.07% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 87.91% | 90.08% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 87.78% | 95.00% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 87.41% | 89.50% |
| CHEMBL220 | P22303 | Acetylcholinesterase | 87.32% | 94.45% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 87.30% | 93.18% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 87.24% | 95.50% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 87.03% | 88.56% |
| CHEMBL2716 | Q8WUI4 | Histone deacetylase 7 | 86.67% | 89.44% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 86.54% | 96.90% |
| CHEMBL1994 | P08235 | Mineralocorticoid receptor | 86.38% | 100.00% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 86.13% | 95.56% |
| CHEMBL1075317 | P61964 | WD repeat-containing protein 5 | 86.07% | 96.33% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 85.16% | 95.89% |
| CHEMBL5028 | O14672 | ADAM10 | 83.18% | 97.50% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 83.11% | 85.31% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 83.02% | 97.25% |
| CHEMBL3713062 | P10646 | Tissue factor pathway inhibitor | 81.61% | 97.33% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 81.19% | 85.00% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 81.02% | 100.00% |
| CHEMBL5469 | Q14289 | Protein tyrosine kinase 2 beta | 80.80% | 91.03% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 80.23% | 99.23% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 138453968 |
| LOTUS | LTS0021384 |
| wikiData | Q105013368 |